Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Imatinib is a key treatment for chronic myeloid leukemia (CML).
• MicroRNAs (miRNAs) regulate gene expression post-transcriptionally.
• The role of miRNAs in imatinib effectiveness in CML is not fully understood.

Purpose of the Study:

• To investigate the role of miR-30a in regulating imatinib efficacy in CML.
• To determine the mechanism by which miR-30a affects imatinib-induced apoptosis.

Main Methods:

• Studied the effect of imatinib on miR-30a expression in human CML cells.
• Utilized miR-30a mimics and antagomirs to modulate miR-30a levels.
• Assessed the impact of miR-30a modulation on autophagy genes (Beclin 1, ATG5) and apoptosis.

Main Results:

• Imatinib significantly inhibited miR-30a expression in CML cells.
• miR-30a acts as an autophagy inhibitor by downregulating Beclin 1 and ATG5.
• Enhancing miR-30a or inhibiting autophagy genes increased imatinib-induced cytotoxicity and apoptosis.
• Knockdown of miR-30a reduced Beclin 1 and ATG5 expression, inhibiting imatinib's cytotoxicity.

Conclusions:

• Dysregulation of miR-30a interferes with imatinib-mediated apoptosis via an autophagy-dependent pathway.
• miR-30a represents a potential therapeutic target for improving imatinib treatment in CML.